NACDS announces winners of Total Store Expo Product Showcase
ARLINGTON, Va. — The National Association of Chain Drug Stores has announced the winners of the 2013 NACDS Total Store Expo Product Showcase.
The 160 products, ranging from health and beauty to seasonal items, were on display in the “Product Showcase” on the exhibit floor. The Showcase provided increased visibility for suppliers marketing products.
Evaluated by the retail attendees, winners of this year’s “Product Showcase” are:
Company/booth: Fleet Laboratories / Booth 3240
Product: Boudreaux’s Butt Paste
Company/booth: The Jel Sert Company / Booth 3249
Product: Super C Vitamin Drink Mix
Cosmetics & Fragrances
Company/booth: Beauty 21 / LA Colors / LA Girl / Booth 5045
Product: Hot New Nail Products
Company/booth: Pet Head Inc. / Booth 5057
Product: Pet Dry Shampoo
Company/booth: BrookLands Inc. / Booth 3360
Company/booth: ChoiceMMed America Co / Booth 4749
Product: Lung Boost Respiratory Trainer
Household Products/Non-Edible Consumables
Company/booth: ShurTech Brands, LLC / Booth 3257
Product: Disney Licensed Duck Tape
Company/booth: Wahl Clipper Corp./ Booth 3058
Product: Grooms Man Trimmer
Pharmacy Operations Equipment & Services
Company/booth: AccessaMed, Inc. / Booth 5002
Product: Digital Audio Label
Company/booth: Mylan Inc. / Booth 3426
Product: EpiPen Jr.
Company/booth: IMPLUS Foot Care / Booth 3349
Product: Little Hotties Warmers
CareMed selected to distribute Tarceva
LAKE SUCCESS, N.Y. — Specialty pharmacy CareMed Pharmaceutical Services has been added to a limited-distribution network for a cancer drug sold by Genentech and Astellas Pharma, the company said.
CareMed said it had been selected to supply the drug, Tarceva (erlotinib). The two drug makers stopped distributing the drug, a once-daily treatment for advanced lung cancer, through retail pharmacies at the beginning of July.
"CareMed is honored to be able to continue supplying our patients with Tarceva," CareMed SVP sales and marketing John Witkowski said. "In 2013, the American Cancer Society estimates 228,000 Americans will be diagnosed with lung cancer, with [non-small cell lung cancer] accounting for 85% of lung cancer cases. Of these, the majority of people diagnosed will already be in an advanced stage of the disease."
CHPA files citizen petition to allow liquid APAP dosing recommendations for children 6 months to 2 years
WASHINGTON — The Consumer Healthcare Products Association on Monday asked the Food and Drug Administration to take action to ensure that the millions of caretakers who use acetaminophen products in young children have access to convenient and accurate dosing information. Representing makers of over-the-counter single-ingredient liquid acetaminophen medicines for children, CHPA submitted a citizen petition requesting that the FDA publish a “statement of enforcement policy” permitting manufacturers of OTC single-ingredient liquid pediatric acetaminophen products to include dosing information for children ages 6 months to 2 years on the Drug Facts label of these medicines.
While acetaminophen is approved for use in young children, the currently allowed labeling under tentative final monograph includes only “ask a doctor” in the dosing directions for children ages 6 months to 2 years.
“The peak of acetaminophen usage in children is for those ages 6 months to 23 months, yet the labeling of these products lacks instructions for this population,” stated Barbara Kochanowski, CHPA VP of regulatory and scientific affairs. “Young children can spike a fever at any time of the day or night, and to get dosing information for children under 2, caretakers must proactively seek out information from a healthcare provider rather than having the convenience of instructions printed on the Drug Facts label," she said. “Providing clear, consistent instructions directly on the label will help ensure that caretakers appropriately dose children under 2 years of age, potentially reducing the likelihood of dosing errors and dosing ‘guesses’ in the middle of the night.”
In its citizen petition, CHPA requested permission for manufacturers to include pediatric dosing for children ages 6 months to 2 years on product labels moving forward, while rulemaking around the monograph is finalized. CHPA recommended a single, standardized age and weight-based chart — based on the researched and established dosing recommendations of multiple pediatric and primary care medical association treatment guidelines — which all manufacturers could adopt.
In May 2011, a joint FDA Pediatric Advisory Committee and Nonprescription Drugs Advisory Committee unanimously recommended that OTC single-ingredient liquid pediatric acetaminophen products include dosing information for children ages 6 months to 2 years.
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.